Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Laura Amanda Vallejo-Aparicio"'
Autor:
Alberto Pérez, María Fernández Prada, Natalia Cassinello, Laura Amanda Vallejo-Aparicio, Andrea García, Almudena González, Ana Durán, Néboa Zozaya, Irene Fernández, Mathilde Daheron, Álvaro Hidalgo, Ekkehard Beck, Antonio García Ruiz
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
Broad benefits of vaccination programs are well acknowledged but difficult to measure, especially when considering all vaccines included in a National Immunization Program (NIP). The aim was to conduct a cost–benefit analysis of the entire NIP in S
Externí odkaz:
https://doaj.org/article/a07e7f9c0aac4baaa68559c51f8f7122
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
The recombinant zoster vaccine (RZV) is included in the Spanish National Immunisation Programme for adults 65 years of age (years), with a potential progressive catch-up program for adults 66–80 years, starting with 80 years. However, the risk of h
Externí odkaz:
https://doaj.org/article/e3f807443dce4a85a5d6b89e6c3dd195
Autor:
Santiago Moreno, Antonio Rivero, Pere Ventayol, Vicenç Falcó, Miguel Torralba, Melanie Schroeder, Victoria Neches, Laura Amanda Vallejo-Aparicio, Isaac Mackenzie, Matthew Turner, Cale Harrison
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 8, Pp 2039-2055 (2023)
Abstract Introduction Current antiretroviral therapies (ARTs) have improved outcomes for people living with HIV. However, the requirement to adhere to lifelong daily oral dosing may be challenging for some people living with HIV, leading to suboptima
Externí odkaz:
https://doaj.org/article/96a2af1b7a3242eeb997071c78f425c5
Autor:
Victoria Federico Paly, Laura Amanda Vallejo-Aparicio, Alan Martin, José Luis Izquierdo, Juan Antonio Riesco, Juan José Soler-Cataluña, Catarina Abreu, Chandroday Biswas, Afisi S Ismaila
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease. 17:3097-3109
Victoria Federico Paly,1 Laura Amanda Vallejo-Aparicio,2 Alan Martin,3 José Luis Izquierdo,4 Juan Antonio Riesco,5 Juan José Soler-Cataluña,6 Catarina Abreu,7 Chandroday Biswas,8 Afisi S Ismaila9,10 1ICON plc, Philadelphia, PA, USA; 2GSK, Ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4148a717e2cb462504082f15f79f9ce9
https://doi.org/10.2147/copd.s366765
https://doi.org/10.2147/copd.s366765
Autor:
Ángel Gil de Miguel, José María Eiros Bouza, Luis Ignacio Martínez Alcorta, Daniel Callejo, Carlos Miñarro, Laura Amanda Vallejo-Aparicio, Andrea García, Mónica Tafalla, María del Rosario Cambronero, Rubén Rodríguez, Laura Martin-Gomez
Publikováno v:
PharmacoEconomics - Open. 6:509-518
Protection against vaccine-preventable diseases is especially relevant in older adults due to age-related decline in immunity (immunosenescence). However, adult vaccination remains a challenge with overall low coverage rates, which has an impact on b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cd6f5cdb5064ea5ce8528666703b674
https://doi.org/10.1007/s41669-022-00329-3
https://doi.org/10.1007/s41669-022-00329-3
Autor:
Maria del Carmen Gonzalez-Inchausti, Yoana Ivanova-Markova, Álvaro Hidalgo, Rubén Campuzano Rodríguez, Antonio García-Ruiz, Almudena González-Domínguez, Jing Shen, Najida Begum, Andrea Sánchez García, Monica Tafalla, Nuria García-Agua, Laura Amanda Vallejo-Aparicio, Raquel Sánchez, Eduardo de Gomensoro
Publikováno v:
Vaccine. 39:7646-7654
Introduction Invasive meningococcal disease (IMD) is a severe infectious disease, mainly affecting children under 5 years, associated with long-term physical, neurological and psychological sequelae. In Spain, most IMD cases are caused by meningococc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::030f1b0b09bdc717f068ba211e28d6d1
https://doi.org/10.1016/j.vaccine.2021.11.006
https://doi.org/10.1016/j.vaccine.2021.11.006
Autor:
Miguel Ángel, Calleja-Hernández, José Manuel, Martinez-Sesmero, Laura Amanda, Vallejo-Aparicio, Beatriz, Hernández-Novoa, Xavier, Badia
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 46(4)
To determine the value contribution of cabotegravir + rilpivirine, the first injectable every two months long-acting antiretroviral regimen, using multi-criteria decision analysis.The study was developed in two phases. After a small pilot, a field or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0def1f77bd928c797f1392296bc64d5e
https://pubmed.ncbi.nlm.nih.gov/36183218
https://pubmed.ncbi.nlm.nih.gov/36183218
Autor:
Victoria Neches García, Laura Amanda Vallejo-Aparicio, Afisi S Ismaila, Antoni Sicras-Mainar, Aram Sicras-Navarro, Cruz González, Rafael Cuervo, Soham Shukla, Marcos García-Peñuela
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease.
Victoria Neches GarcÃa,1 Laura Amanda Vallejo-Aparicio,1 Afisi S Ismaila,2,3 Antoni Sicras-Mainar,4 Aram Sicras-Navarro,4 Cruz González,5 Rafael Cuervo,6 Soham Shukla,2 Marcos GarcÃa-Peñuela6 1Market Access, GlaxoSmithKline, Madrid, Spain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df3b7f4b629c5536ea76b63736a9349e
https://www.dovepress.com/clinical-and-economic-impact-of-long-term-inhaled-corticosteroid-withd-peer-reviewed-fulltext-article-COPD
https://www.dovepress.com/clinical-and-economic-impact-of-long-term-inhaled-corticosteroid-withd-peer-reviewed-fulltext-article-COPD
Autor:
Laura Amanda Vallejo-Aparicio, Jesús Molina, Iñigo Ojanguren, Ana Viejo Casas, Alicia Huerta, Henrik Svedsater
Publikováno v:
The European Journal of Health Economics
Eur J Health Econ
Eur J Health Econ
Objectives The Salford Lung Study in asthma (SLS asthma) is a 12-month, open-label randomised clinical trial comparing clinical effectiveness of initiating once-daily inhaled combination of fluticasone furoate/vilanterol (FF/VI) 184/22 mcg or 92/22 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cfeafd759aa125292f1507fe11ec25d
http://europepmc.org/articles/PMC7058572
http://europepmc.org/articles/PMC7058572
Autor:
Laura Amanda Vallejo-Aparicio, J.M. Molero, Francisco José Brenes, José Manuel Cozar, Alicia Huerta, Bernardino Miñana López, A. Fernández-Pro
Publikováno v:
PharmacoEconomics Spanish Research Articles. 14:39-48
Estimar la ratio coste-efectividad incremental (RCEI) de la combinacion dutasterida/tamsulosina (DUT/TAM) como tratamiento de inicio frente a la practica clinica de espera vigilada (EV) mas escalado a tamsulosina (EV + TAM), en pacientes con hiperpla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ffcd1ab904fe46442b835f21092c728e
https://doi.org/10.1007/s40277-017-0069-y
https://doi.org/10.1007/s40277-017-0069-y